查詢結果分析
來源資料
相關文獻
- The Prevalence of KRAS Gene Mutation in Colorectal Cancer Patients with Epidermal Growth Factor Receptor Expression
- 結腸直腸癌的輔助性治療
- 結腸直腸癌合併腦部轉移之治療
- 轉移性結腸直腸癌化學治療之新貌
- 5-氟尿嘧啶單獨或併用游離輻射治療人類結腸直腸癌細胞之效果
- 結腸直腸癌
- 預後營養指數在結腸直腸手術的價值
- 胰臟癌與結腸直腸癌的探討
- 轉移性結腸直腸癌(Metastatic Colorectal Cancer)新一代口服治療藥物-fluoropyrimidines
- Postoperative Essential Fatty Acid Deficiency in Patients with Colorectal Cancer
頁籤選單縮合
題 名 | The Prevalence of KRAS Gene Mutation in Colorectal Cancer Patients with Epidermal Growth Factor Receptor Expression=上皮細胞生長因子受體表現陽性之結腸直腸癌患者KRAS突變盛行率 |
---|---|
作 者 | 范紀鎮; 孔建民; | 書刊名 | 健康管理學刊 |
卷 期 | 12:2 2014.12[民103.12] |
頁 次 | 頁30-40 |
分類號 | 416.245 |
關鍵詞 | 結腸直腸癌; 標靶藥物治療; KRAS; Colorectal cancer; Targeted drug therapy; EGFR; KRAS; |
語 文 | 英文(English) |
中文摘要 | 標靶藥物療法通常用於治療結腸直腸癌患者。臨床上,結腸直腸癌組織KRAS基因突變狀態可以決定是否能夠接受對抗上皮細胞生長因子受體(epidermal growth factor receptor, EGFR)之標靶藥物治療的選擇之一。本研究要探討臺灣目前在上皮細胞生長因子受體陽性的結腸直腸癌組織中,KRAS基因突變的盛行率。分析在臺北馬偕醫院已接受治療的164例結腸直腸癌患者(平均年齡61.80±12.78年)。癌瘤組織經免疫化學染色法測定後,選出48例癌瘤組織中EGFR表現陽性樣本,再經桑格(Sanger)定序法分析癌瘤組織中KRAS基因突變狀態。結果在48例癌瘤組織樣本中發現有高達50%之KRAS基因在密碼子12和13上出現突變現象,並且有41.67%是發生在轉移性結腸直腸癌患者組織上。KRAS基因密碼子12的突變率有75.00%,特別是甘氨酸轉成天門冬氨酸(G12D,50.00%)和甘氨酸轉成纈氨酸(G12V,12.50%)。KRAS基因密碼子13突變率有25.00%,主要是甘氨酸轉成天門冬氨酸(G13D,25.00%)。本研究發現有高的KRAS基因突變率出現在EGFR表現陽性的結腸直腸癌組織中。 |
英文摘要 | Anti-epidermal growth factor receptor targeted therapy is typically used to treat colorectal cancer (CRC). The KRAS gene status is one of eligible situations for treating CRC patients with targeting drugs. This study was to clarify the recent prevalence of KRAS gene mutation in CRC patients with epidermal growth factor receptor (EGFR) expression in Taiwan. One hundred and sixty-four patients (mean age, 61.80±12.78 years) who suffered from CRC were enrolled in this study at Mackay Memorial Hospital in Taiwan. Among those CRC paraffin-embedded tissues, 48 subjects with EGFR expression were detected by immunohistochemical method, and those Kirsten RAS (KRAS) gene were amplified using the Sanger sequencing method. The KRAS mutations in codons 12 and 13 were found in 50.00% of all EGFR-expressing CRC patients, and in 41.67% of metastatic CRC patients. The most frequent mutations were those on codon 12 (75.00%), especially glycine-to-aspartate (G12D, 50.00%) and glycine-to-valine (G12V, 12.50%) mutations. A 25.00% mutation on codon 13 was mostly glycine-to-aspartate (G13D, 25.00%). This study identified a high frequency of KRAS somatic mutation in CRC with EGFR expressed patients. |
本系統中英文摘要資訊取自各篇刊載內容。